Efficacy and Safety of Subantimicrobial Dose, Modified-Release Doxycycline 40 mg Versus Doxycycline 100 mg Versus Placebo for the treatment of Inflammatory Lesions in Moderate and Severe Acne: A Randomized, Double-Blinded, Controlled Study

Routine use of doxycycline (DC) 100 mg for the treatment of moderate to severe acne may be associated with gastrointestinal adverse events (AEs), thus potentially impacting patient adherence, and antibiotic resistance. This study evaluated the safety and efficacy of subantimicrobial, modified-releas...

Full description

Saved in:
Bibliographic Details
Published inJournal of drugs in dermatology Vol. 14; no. 6; p. 581
Main Authors Moore, Angela, Ling, Mark, Bucko, Alicia, Manna, Vasant, Rueda, Marie-Jose
Format Journal Article
LanguageEnglish
Published United States 01.06.2015
Subjects
Acne Vulgaris - drug therapy
Adolescent
Adult
Aged
Anti-Infective Agents - administration & dosage
Anti-Infective Agents - adverse effects
Anti-Infective Agents - therapeutic use
Child
Delayed-Action Preparations
Double-Blind Method
Doxycycline - administration & dosage
Doxycycline - adverse effects
Doxycycline - therapeutic use
Female
Humans
Male
Middle Aged
Treatment Outcome
Young Adult
Online AccessGet more information

Cover

More Information
Summary:Routine use of doxycycline (DC) 100 mg for the treatment of moderate to severe acne may be associated with gastrointestinal adverse events (AEs), thus potentially impacting patient adherence, and antibiotic resistance. This study evaluated the safety and efficacy of subantimicrobial, modified-release (MR) DC 40 mg compared to DC 100 mg and to placebo for the treatment of inflammatory lesions in moderate and severe acne. 662 subjects aged 12 years or older with moderate to severe acne received subantimicrobial, MR-DC 40 mg tablets, DC 100 mg capsules, or placebo once daily for 16 weeks. MR-DC 40 mg was superior to placebo in the mean reduction of the number of inflammatory lesions, median percent reduction in inflammatory and total lesions, and success rate. MR-DC 40 mg was also comparable to DC 100 mg in the reduction of the number of inflammatory lesions, and percent reduction of total lesions. Incidence of drug-related AEs for MR-DC 40 mg was similar to placebo and was markedly smaller compared to DC 100 mg. MR-DC 40 mg demonstrated comparable efficacy and superior safety to DC 100 mg in the treatment of moderate to severe inflammatory acne.
ISSN:1545-9616